We are a leading edge pharmaceutical company and are a member of the BEXIMCO Group, the largest private sector industrial conglomerate in Bangladesh. Our strategic strengths include strong recognition of our brands, highly skilled work force and diversified business mix. Our two brands - Neoceptin R (Ranitidine) and Napa (Paracetamol) are the top two selling brands in the Bangladesh Pharmaceutical market.  We started our operation in 1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of USA and now have grown to become nation's one of the leading pharmaceutical companies, supplying more than 10% of country's total medicine need. Today Beximco Pharma manufactures and markets its own `branded generics' for almost all diseases from AIDS to cancer, own

`branded generics' for almost all diseases from AIDS to cancer, from infection to asthma, from hypertension to diabetes for both nationall and internationall markets.

 We manufacture a range of dosage forms including tablets, capsules, dry syrup, powder, cream, ointment, suppositories, large volume intravenous fluids, metered dose inhalers etc. in several world-class manufacturing plants, ensuring high quality standards complying with the World Health Organization (WHO) approved current Good Manufacturing Practices (cGMP). We also contract manufacture for major international brands of leading multinational companies.

The recipient of three times `gold' national export trophy, Beximco Pharma is the largest exporter of pharmaceuticals from Bangladesh. We are the only pharmaceutical company in Bangladesh received this highest national accolade for export, for record three times. We market our brands through our own professional sales and marketing teams in African, South Asian and other markets. We also supply our products to renowned hospitals and institutions in many countries, including Raffles Hospital and K K Women & Childrens' Hospital in Singapore, MEDS and Kenyatta National Hospital (KNH) in Kenya, Jinnah Hospital, Agha Khan Hospital and Shaukat Khanum Memorial Hospital in Pakistan. We are also an enlisted supplier of World Health Organization (WHO) and UNICEF.

 We have a strong market focus and are anticipating continued future growth by leveraging business capabilities and developing superior product brands and markets. In particular we are very interested in developing a strong export market in USA and Europe. To meet the future demand we have invested over US 50 million dollar to build a new state-of-the-art manufacturing plant, confirming to USFDA and UK MHRA standards. This new plant will also offer contract-manufacturing facility to leading pharmaceutical companies, especially from Europe and US.